1131 KB35 KB199420252005Kristl, Jernejštevilka:2letnik:44str. 171-182ISSN:0025-8121COBISSID:1776241URN:URN:NBN:SI:doc-VWQB2IDBslMedicinski razglediMedicinski razgledicitokinifarmakologijakožne bolezniluskavicamonoklonalna protitelesarekombiantni proteinitherapyzdravljenjeRekombinantni človeški proteini - nov nabor učinkovin za zdravljenje luskavice| Recombinant human protein - new palette of drugs for the treatment of psoriasis|Psoriasis is a chronic, inflammatory disease, which is estimated to affect 2,5% of the worldćs population. Clinically it is characterized by thickened, silvery white, scaly plaques, that can produce considerable discomfort and pain in patients. For the treatment of psoriasis are currently mainly used corticosteroids, vitamin D analogs, ultraviolet A radiation and retinoids, allof which are nonspecific and unable to block the outbreak of disease. Advances in recombinant DNA technology and increased understanding of the pathophysiology of psoriasis have led to the development of numerous immunomodulatory drugs, which specifically inhibit the occurrence of disease. Novel agents have direct effect on T cell, T cell activation, T cell migration, and expression of inflammatory mediators. However, they can still not assure total remission, but offer enhanced efficacy and improved safety. We have to take into consideration that treatment of psoriasis is usually longterm, meaning that adverse effects of a drug represent a limiting factor for using that drug. In this article, known facts on psoriasis are presented, along with the review of therapies with stress on new immunomodulatory agentsLuskavica je kroniena vnetna bolezen, ki prizadene priblizno 2,5 % svetovnega prebivalstva. Klinieno se kaze z odebeljenimi, srebrno-belimi in luskastimi zarisei na kozi, ki lahko pri bolniku povzroeijo hudo nelagodje in boleeino. Za zdravljenje luskavice se veeinoma uporabljajo kortikosteroidi, analogi vitamina D, obsevanje z ultravijolieno A-svetlobo, retinoidi, vendar so obstojeei naeini zdravljenja nespecifieni in le zavirajo mehanizme njenega nastanka. Napredek rekombinantne DNA-tehnologije in boljse poznavanje patofiziologije luskavice sta botrovala razvoju stevilnih imunomodulacijskih beljakovinskih ueinkovin, ki specifieno zavirajo nastanek luskavice. Bioloske ueinkovine delujejo z neposrednim vplivom na limfocite T, njihovo aktivacijo, migracijo ter izrazanje vnetnih mediatorjev. Kljub vsemu ozdravljenja ne zagotovijo, vendar ueinkoviteje lajsajo njene bolezenske znake, poleg tega so vedno bolj varna. Upostevati moramo namree, da je zdravljenje luskavice navadno dolgotrajno, med katerim je prisotnost nezelenih ueinkov pri veeini ueinkovin omejitveni dejavnik. V tem elanku so predstavljena znana dejstva o luskavici, v nadaljevanju pa sledi pregled ueinkovin za njeno zdravljenje s poudarkom na novejsih imunomodulacijskih ueinkovinahTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaDruštvo Medicinski razgledi